International Scholarly Research Notices / 2012 / Article / Tab 6 / Review Article
Venous Thromboembolism in Cancer Patients Undergoing Major Abdominal Surgery: Prevention and Management Table 6 Comparison of VTE pharmacoprophylactic recommendations laid down by ASCO, ACCP, NCCN, National Guideline Clearing House, and ESMO.
Guideline last updated in Drug Duration Unfractionated heparin Dalteparin Enoxaparin Fondaparinux ASCO [127 ] 2007 5,000 U sc every 8 hours 5,000 U sc daily 40 mg sc daily 2.5 mg sc daily Up to 7–10 days postop. Up to 4 weeks post op in high risk patients ACCP [129 ] 2008 5,000 U sc every 8 hours 5,000 IU sc daily 40 mg sc daily Not recommended Up to 4 weeks after discharge NCCN [205 ] 2011 5,000 U sc every 8 hours 5,000 IU sc daily 40 mg sc daily 2.5 mg sc daily Up to 4 weeks postop ESMO [128 ] 2011 5,000 U sc every 8 hours 5,000 U sc daily 40 mg sc daily 2.5 mg sc daily Up to discharge or until ambulatory National Guideline Clearinghouse [204 ] 2011 5,000 U sc every 12 hr postop 2,500 units sc 1-2 hr preop, then every 24 hr 40 mg sc 2 hr preop, then every 24 hr Not recommended Up to 4 weeks postop
VTE: venous thromboembolism, ASCO: American Society for Oncology, ACCP: American College of Chest Physicians, NCCN: National Comprehensive Cancer Network, ESMO: European Society Of Medical Oncology; LMWH: low molecular weight heparin, sc: subcutaneously, postop: postoperatively.